The pathophysiology of paroxysmal nocturnal hemoglobinuria and treatment with eculizumab

Por Kelly, Richard, Richards, Stephen, Hillmen, Peter, Hill, Anita
Publicado em 2009

The Management of Paroxysmal Nocturnal Hemoglobinuria: Recent Advances in Diagnosis and Treatment and New Hope for Patients

Por Young, Neal S., Meyers, Gabrielle, Schrezenmeier, Hubert, Hillmen, Peter, Hill, Anita
Publicado em 2009

Polymyalgia rheumatica development in a patient under PI3K inhibitor therapy for chronic lymphocytic leukaemia

Por Sajawal, Sanah, Mackie, Sarah L, Hillmen, Peter, McGonagle, Dennis
Publicado no BMJ Case Rep (2017)

Experiences in the design and implementation of phase II trials in CLL

Por Cohen Dena R, Hillmen Peter, Brown Julia M, Gregory Walter M
Publicado em 2011-12-01

Experiences in the design and implementation of phase II trials in CLL

Por Cohen, Dena R, Hillmen, Peter, Brown, Julia M, Gregory, Walter M
Publicado em 2011

Ibrutinib for chronic lymphocytic leukemia: international experience from a named patient program

Por Hillmen, Peter, Diels, Joris, Healy, Nollaig, Iraqi, Wafae, Aschan, Johan, Wildgust, Mark
Publicado no Haematologica (2018)

DAPK3 participates in the mRNA processing of immediate early genes in chronic lymphocytic leukaemia

Por Thomas, Fraser, Holmes, Katie B., Kreuz, Sarah, Hillmen, Peter, Lefevre, Pascal F.
Publicado no Mol Oncol (2020)

Significant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuria

Por Griffin, Morag, Hillmen, Peter, Munir, Talha, Richards, Stephen, Arnold, Louise, Riley, Kathryn, Hill, Anita
Publicado no Haematologica (2019)

An increased fraction of circulating miR-363 and miR-16 is particle bound in patients with chronic lymphocytic leukaemia as compared to normal subjects

Por Alharthi, Afaf, Beck, Daniel, Howard, Dena R., Hillmen, Peter, Oates, Melanie, Pettitt, Andrew, Wagner, Simon D.
Publicado no BMC Res Notes (2018)

Telomere length predicts for outcome to FCR chemotherapy in CLL

Por Norris, Kevin, Hillmen, Peter, Rawstron, Andrew, Hills, Robert, Baird, Duncan M., Fegan, Christopher D., Pepper, Chris
Publicado no Leukemia (2019)

Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization

Por Hill, Anita, Rother, Russell P., Arnold, Louise, Kelly, Richard, Cullen, Matthew J., Richards, Stephen J., Hillmen, Peter
Publicado em 2010

Different Biology and Clinical Outcome According to the Absolute Numbers of Clonal B-Cells in Monoclonal B-Cell Lymphocytosis (MBL)

Por Rawstron, Andy C., Shanafelt, Tait, Lanasa, Mark C., Landgren, Ola, Hanson, Curtis, Orfao, Alberto, Hillmen, Peter, Ghia, Paolo
Publicado no Cytometry B Clin Cytom (2010)

Ibrutinib induces chromatin reorganisation of chronic lymphocytic leukaemia cells

Por Holmes, Katie B., Sadreev, Ildar I., Rawstron, Andy C., Munir, Tal, Westhead, David R., Hillmen, Peter, Lefevre, Pascal F.
Publicado no Oncogenesis (2019)

The STELLAR trial protocol: a prospective multicentre trial for Richter’s syndrome consisting of a randomised trial investigation CHOP-R with or without acalabrutinib for newly dia...

Por Appleby, Niamh, Eyre, Toby A., Cabes, Maite, Jackson, Aimee, Boucher, Rebecca, Yates, Francesca, Fox, Sonia, Rawstron, Andrew, Hillmen, Peter, Schuh, Anna
Publicado no BMC Cancer (2019)

COVID‐19 infection in patients on anti‐complement therapy: The Leeds National Paroxysmal Nocturnal Haemoglobinuria service experience

Por Pike, Alexandra, Muus, Petra, Munir, Tahla, Mitchell, Lindsay, Arnold, Louise, Riley, Kathryn, Houghton, Nicola, Forrest, Briony, Gachev, Jeanifer, Hillmen, Peter, Griffin, Morag
Publicado no Br J Haematol (2020)

A platform trial in practice: adding a new experimental research arm to the ongoing confirmatory FLAIR trial in chronic lymphocytic leukaemia

Por Howard, Dena R., Hockaday, Anna, Brown, Julia M., Gregory, Walter M., Todd, Susan, Munir, Tahla, Oughton, Jamie B., Dimbleby, Claire, Hillmen, Peter
Publicado no Trials (2021)

Chemotherapy plus Ofatumumab at Standard or Mega dose in relapsed CLL (COSMIC) trial: study protocol for a phase II randomised controlled trial

Por Howard, Dena R., Munir, Talha, Hockaday, Anna, Rawstron, Andy C., Collett, Laura, Oughton, Jamie B., Allsup, David, Bloor, Adrian, Phillips, David, Hillmen, Peter
Publicado no Trials (2016)

How We Manage Patients With Chronic Lymphocytic Leukemia During the SARS-CoV-2 Pandemic

Por Rossi, Davide, Shadman, Mazyar, Condoluci, Adalgisa, Brown, Jennifer R., Byrd, John C., Gaidano, Gianluca, Hallek, Michael, Hillmen, Peter, Mato, Anthony, Montserrat, Emili, Ghia, Paolo
Publicado no Hemasphere (2020)

Diagnosis and management of paroxysmal nocturnal hemoglobinuria

Por Parker, Charles, Omine, Mitsuhiro, Richards, Stephen, Nishimura, Jun-ichi, Bessler, Monica, Ware, Russell, Hillmen, Peter, Luzzatto, Lucio, Young, Neal, Kinoshita, Taroh, Rosse, Wendell, Socié, Gerard
Publicado em 2005

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis

Por Socié, Gérard, Caby‐Tosi, Marie‐Pierre, Marantz, Jing L., Cole, Alexander, Bedrosian, Camille L., Gasteyger, Christoph, Mujeebuddin, Arshad, Hillmen, Peter, Vande Walle, Johan, Haller, Hermann
Publicado no Br J Haematol (2019)